Highlights frameworks for early lung cancer detection pathways which intersect with bronchoscopic diagnostic procedures in underserved populations.
Clinical context
The 9th edition of the TNM classification, effective January 2025, introduces granular changes to N and M descriptors that directly impact staging and therapeutic decision-making. For the Interventional Pulmonologist, the subdivision of N2 into N2a (single station) and N2b (multiple stations) necessitates a shift toward more precise, systematic mediastinal sampling to avoid under-staging, which now carries significant prognostic and treatment-allocation implications.
Strengths and weaknesses
Takeaway
1. Precision Matters: With the N2a/N2b split, your staging report must explicitly document the specific nodal stations sampled. 2. Contamination Risk: Be aware that the majority of practitioners do not change needles between N2 stations, yet the clinical impact of potential cross-contamination remains an open question—await results from NCT07418450. 3. Technological Evolution: While conventional EBUS remains the gold standard, thin convex-probe EBUS and robotic-assisted platforms are expanding our reach into subsegmental (N1) and peripheral (stations 5/6) nodes, which may soon become part of routine staging. 4. Molecular Yield: Prioritize cryo-EBUS or high-quality core acquisition when molecular profiling is the primary goal, especially in never-smokers.
Abstract
Keep reading
N opens the next oneDirectly impacts IP practice by highlighting the critical role of bronchoscopic sampling techniques in providing adequate tissue for molecular profiling.
Highlights the critical importance of obtaining adequate tissue via bronchoscopic biopsies for comprehensive molecular profiling.
Relevant to ablative therapies often managed or co-evaluated by interventional pulmonologists in the multidisciplinary management of lung malignancies.
Relevant for IP specialists involved in the bronchoscopic and image-guided tissue diagnosis and staging of apical lung masses.
Relevant to IP practices managing pulmonary nodules discovered during staging or diagnostic workups.